Dr. Robert Redfield, the head of the Centers for Disease Control and Prevention, and Dr. Stephen Hahn, the commissioner of the Food and Drug Administration, will testify by video conference at a Senate hearing about the coronavirus next week.
A spokesperson for DHS reportedly declined to comment on the number of cases.
He will be staying at home and teleworking while wearing a mask continually for 14 days.
U.S. Food and Drug Administration Commissioner Stephen Hahn is in self-quarantine for a couple of weeks after coming into contact with someone who tested positive for COVID-19, an FDA spokesman told Reuters late on Friday.
Those practices made the tests sent to public health labs unusable because they were contaminated with the coronavirus, and produced some inconclusive results.
The FDA’s director of the Office of In Vitro Diagnostics and Radiological Health, Timothy Stenzel, flew to CDC headquarters in Atlanta on the weekend of Feb. 22, but he was immediately forced to wait overnight as health department officials lobbied the CDC to give him access to the agency’s campus, according to Politico. Stenzel was there specifically to work out issues with the CDC’s coronavirus test that had already hobbled more expansive screening for weeks.
A senior administration official added that the government also moved the manufacturing of the coronavirus tests out of the Atlanta laboratory of CDC.
The official said that the CDC engaged with a third party contractor on Feb. 20 to help manufacture the testing kits. The official added that the FDA regulator, Stenzel, visited the Atlanta laboratory on Feb. 22.
(August 7, 2014)
Favipiravir is in the final stages of human studies in the U.S. as a treatment for flu. A Phase II study in the U.S. using 10 grams of the drug showed the medicine reduced flu symptoms against a placebo. The U.S. phase III study of the treatment for flu is scheduled to be completed around March 2015, the company said last month.
The U.S. Department of Defense funded the trials to improve the country’s response capability and protect the military from flu pandemics, its BioDefense Therapeutics unit said in an October statement.
The Department of Health and Human Services said Sunday hydroxychloroquine and chloroquine products can be distributed and prescribed by doctors through the Strategic National Stockpile “to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible.”
HHS said Germany’s Sandoz has already given 30 million doses of hydroxychloroquine to the Strategic National Stockpile, the federal government’s inventory of medical supplies for public health emergencies, while Bayer has donated a million doses of chloroquine.
Lawson discussed how drugmaker Gilead Sciences asked the Food and Drug administration last week to give it the rare „orphan“ status for remdesivir, the company’s experimental coronavirus treatment.
“It’s shown very encouraging, very, very encouraging early results, and we’re going to be able to make that drug available almost immediately, and that’s where the FDA has been so great,” Trump said. “They’ve gone through the approval process, it’s been approved and they did it, they took it down from many, many months to immediate.”
But moments later, FDA Commissioner Stephen Hahn cautioned that chloroquine had not yet been approved for treating COVID-19.